Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7918055 | 0.92 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL16002889 | 0.88 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL6226662 | 0.80 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL4974553 | 0.80 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL23603002 | 0.78 | — | — | |
| SCHEMBL15818137 | 0.78 | — | — | |
| SCHEMBL4838694 | 0.78 | — | — | |
| SCHEMBL15166346 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL5559301 | 0.78 | ALDH1A1 (0.37) | SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL5559307 | 0.78 | ALDH1A1 (0.37) | SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | SLC6A3 457/4885SLC6A2 1121/4885SLC6A4 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.